Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-03-28 DOI:10.1016/j.vaccine.2025.127062

Dominique Gagnon , Charlotte Gubany , Manale Ouakki , Benjamin Malo , Maude Paquette , Nicholas Brousseau , Jesse Papenburg , Eve Dubé

{"title":"Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study","authors":"Dominique Gagnon , Charlotte Gubany , Manale Ouakki , Benjamin Malo , Maude Paquette , Nicholas Brousseau , Jesse Papenburg , Eve Dubé","doi":"10.1016/j.vaccine.2025.127062","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Respiratory syncytial virus (RSV) is a major cause of respiratory infections and hospitalizations in Canadian infants. Recently, Health Canada approved two novel immunizing products: a vaccine given during pregnancy and a monoclonal antibody for infants. This study assessed knowledge, attitudes, and intentions regarding RSV and its prevention among pregnant individuals.</div></div><div><h3>Methods</h3><div>A mixed-methods study was conducted in Quebec from October to December 2023. Pregnant individuals were recruited through targeted Facebook advertisements. Data were collected in two phases: Phase 1 involved an online survey to assess knowledge of RSV, attitudes toward immunization, and intentions regarding both immunization products, followed by qualitative interviews in Phase 2 to explore factors impacting decision-making and preferences for RSV prevention. Survey data were analyzed using descriptive statistics; interview data were analyzed through thematic analysis.</div></div><div><h3>Results</h3><div>Among survey participants (<em>n</em> = 803), 68.4 % reported some knowledge of RSV. Intention for both immunization products was high, with 88.1 % of participants willing to receive the RSV vaccine during pregnancy and 92 %, to administer monoclonal antibodies to their infants. A majority (69 %) of participants preferred vaccination during pregnancy over monoclonal antibodies. The desire to protect their infant from severe RSV complications was a key motivating factor of acceptance of new RSV immunizing products. Other key determinants included vaccine safety, efficacy, and recommendations by healthcare providers. Qualitative interviews (<em>n</em> = 25) highlighted safety concerns of expectant parents about these new products. The importance of clear and evidence-based recommendations by healthcare providers was also emphasized.</div></div><div><h3>Conclusions</h3><div>Pregnant individuals demonstrated a high level of interest in RSV immunization for infants, whether with vaccination during pregnancy or with monoclonal antibodies. Recommendations by healthcare providers and availability of information on the safety and efficacy of these new products will be key to move from intention to action.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127062"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25003597","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Respiratory syncytial virus (RSV) is a major cause of respiratory infections and hospitalizations in Canadian infants. Recently, Health Canada approved two novel immunizing products: a vaccine given during pregnancy and a monoclonal antibody for infants. This study assessed knowledge, attitudes, and intentions regarding RSV and its prevention among pregnant individuals.

Methods

A mixed-methods study was conducted in Quebec from October to December 2023. Pregnant individuals were recruited through targeted Facebook advertisements. Data were collected in two phases: Phase 1 involved an online survey to assess knowledge of RSV, attitudes toward immunization, and intentions regarding both immunization products, followed by qualitative interviews in Phase 2 to explore factors impacting decision-making and preferences for RSV prevention. Survey data were analyzed using descriptive statistics; interview data were analyzed through thematic analysis.

Results

Among survey participants (n = 803), 68.4 % reported some knowledge of RSV. Intention for both immunization products was high, with 88.1 % of participants willing to receive the RSV vaccine during pregnancy and 92 %, to administer monoclonal antibodies to their infants. A majority (69 %) of participants preferred vaccination during pregnancy over monoclonal antibodies. The desire to protect their infant from severe RSV complications was a key motivating factor of acceptance of new RSV immunizing products. Other key determinants included vaccine safety, efficacy, and recommendations by healthcare providers. Qualitative interviews (n = 25) highlighted safety concerns of expectant parents about these new products. The importance of clear and evidence-based recommendations by healthcare providers was also emphasized.

Conclusions

Pregnant individuals demonstrated a high level of interest in RSV immunization for infants, whether with vaccination during pregnancy or with monoclonal antibodies. Recommendations by healthcare providers and availability of information on the safety and efficacy of these new products will be key to move from intention to action.

查看原文本刊更多论文

影响孕妇新生儿接受RSV免疫接种的因素：一项混合方法研究

呼吸道合胞病毒（RSV）是加拿大婴儿呼吸道感染和住院的主要原因。最近，加拿大卫生部批准了两种新的免疫产品：怀孕期间接种的疫苗和婴儿单克隆抗体。本研究评估孕妇对呼吸道合胞病毒及其预防的知识、态度和意图。方法于2023年10 - 12月在魁北克省进行一项混合方法研究。孕妇是通过Facebook定向广告招募的。数据收集分为两个阶段：第一阶段包括在线调查，以评估对RSV的知识、对免疫的态度以及对两种免疫产品的意向；第二阶段进行定性访谈，探讨影响RSV预防决策和偏好的因素。调查资料采用描述性统计分析；访谈数据通过专题分析进行分析。结果803名调查对象中，68.4%的人对呼吸道合胞病毒有一定的了解。对这两种免疫产品的意愿都很高，88.1%的参与者愿意在怀孕期间接种RSV疫苗，92%的参与者愿意给婴儿注射单克隆抗体。大多数（69%）的参与者在怀孕期间更喜欢接种疫苗而不是单克隆抗体。保护婴儿免受严重RSV并发症的愿望是接受新的RSV免疫产品的关键激励因素。其他关键决定因素包括疫苗安全性、有效性和卫生保健提供者的建议。定性访谈（n = 25）强调了准父母对这些新产品的安全担忧。会议还强调了卫生保健提供者提出明确和循证建议的重要性。结论妊娠个体对婴儿RSV免疫表现出高度的兴趣，无论是在妊娠期间接种疫苗还是单克隆抗体。卫生保健提供者的建议以及这些新产品的安全性和有效性信息的可获得性将是将意向转化为行动的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.